These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

819 related articles for article (PubMed ID: 16168294)

  • 1. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.
    Perugini E; Guidalotti PL; Salvi F; Cooke RM; Pettinato C; Riva L; Leone O; Farsad M; Ciliberti P; Bacchi-Reggiani L; Fallani F; Branzi A; Rapezzi C
    J Am Coll Cardiol; 2005 Sep; 46(6):1076-84. PubMed ID: 16168294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cardiac scintigraphy with ⁹⁹mTc-DPD in the differentiation of cardiac amyloidosis subtype.
    de Haro-del Moral FJ; Sánchez-Lajusticia A; Gómez-Bueno M; García-Pavía P; Salas-Antón C; Segovia-Cubero J
    Rev Esp Cardiol (Engl Ed); 2012 May; 65(5):440-6. PubMed ID: 22464102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etiology of amyloidosis determines myocardial 99mTc-DPD uptake in amyloidotic cardiomyopathy.
    Longhi S; Bonfiglioli R; Obici L; Gagliardi C; Milandri A; Lorenzini M; Guidalotti PL; Merlini G; Rapezzi C
    Clin Nucl Med; 2015 May; 40(5):446-7. PubMed ID: 25742226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy.
    Rapezzi C; Quarta CC; Guidalotti PL; Longhi S; Pettinato C; Leone O; Ferlini A; Salvi F; Gallo P; Gagliardi C; Branzi A
    Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):470-8. PubMed ID: 21069320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis.
    Hutt DF; Quigley AM; Page J; Hall ML; Burniston M; Gopaul D; Lane T; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Eur Heart J Cardiovasc Imaging; 2014 Nov; 15(11):1289-98. PubMed ID: 24939945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 99mTc DPD is the preferential bone tracer for diagnosis of cardiac transthyretin amyloidosis.
    Rossi P; Tessonnier L; Frances Y; Mundler O; Granel B
    Clin Nucl Med; 2012 Aug; 37(8):e209-10. PubMed ID: 22785530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis.
    Musumeci MB; Cappelli F; Russo D; Tini G; Canepa M; Milandri A; Bonfiglioli R; Di Bella G; My F; Luigetti M; Grandis M; Autore C; Perlini S; Perfetto F; Rapezzi C
    JACC Cardiovasc Imaging; 2020 Jun; 13(6):1314-1321. PubMed ID: 31864976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unusual high 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) tracer deposition on a heart scintigraphy in a patient with AL amyloidosis: A case report.
    Persia-Paulino YR; Cuevas-Perez J; Fernandez-Asensio R; Junco-Vicente A; Rozado-Castano J; Colunga S; Cigarran H; Calvo J; Laverde A; Persia O; Capin-Sampedro E
    J Nucl Cardiol; 2021 Jun; 28(3):1117-1125. PubMed ID: 32333280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis.
    Quarta CC; Zheng J; Hutt D; Grigore SF; Manwani R; Sachchithanantham S; Mahmood SA; Whelan CJ; Fontana M; Martinez-Naharro A; Chacko L; Lachmann HJ; Gillmore JD; Rapezzi C; Hawkins PN; Wechalekar AD
    Eur Heart J Cardiovasc Imaging; 2021 Oct; 22(11):1304-1311. PubMed ID: 34254119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spleen visualization in both TTR and AL amyloidosis during
    Koutelou M; Tziomalos G; Chatzoglou V; Pappas N; Papanastasiou E; Chatzipavlidou V; Doumas A
    Hell J Nucl Med; 2023; 26(2):140-144. PubMed ID: 37527050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.
    Rapezzi C; Quarta CC; Guidalotti PL; Pettinato C; Fanti S; Leone O; Ferlini A; Longhi S; Lorenzini M; Reggiani LB; Gagliardi C; Gallo P; Villani C; Salvi F
    JACC Cardiovasc Imaging; 2011 Jun; 4(6):659-70. PubMed ID: 21679902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis.
    Galat A; Rosso J; Guellich A; Van Der Gucht A; Rappeneau S; Bodez D; Guendouz S; Tissot CM; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Itti E; Meignan M; Damy T
    Amyloid; 2015; 22(4):210-20. PubMed ID: 26465835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers.
    Piekarski E; Chequer R; Algalarrondo V; Eliahou L; Mahida B; Vigne J; Adams D; Slama MS; Le Guludec D; Rouzet F
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1108-1118. PubMed ID: 29511839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of 99mTc-DPD bone scintigraphy with histological amyloid load in patients with ATTR cardiac amyloidosis.
    Ungericht M; Groaz V; Messner M; Schuetz T; Brunelli L; Zaruba MM; Lener D; Stocker E; Bauer A; Kroiss AS; Mayr A; Röcken C; Poelzl G
    Amyloid; 2024 Mar; 31(1):22-31. PubMed ID: 37530216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction.
    Chen W; Ton VK; Dilsizian V
    Curr Cardiol Rep; 2018 Mar; 20(4):23. PubMed ID: 29520480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early-phase myocardial uptake intensity of
    Abulizi M; Cottereau AS; Guellich A; Vandeventer S; Galat A; Van Der Gucht A; Plante-Bordeneuve V; Dubois-Randé JL; Bodez D; Rosso J; Damy T; Itti E
    J Nucl Cardiol; 2018 Feb; 25(1):217-222. PubMed ID: 27804073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.
    Hutt DF; Fontana M; Burniston M; Quigley AM; Petrie A; Ross JC; Page J; Martinez-Naharro A; Wechalekar AD; Lachmann HJ; Quarta CC; Rezk T; Mahmood S; Sachchithanantham S; Youngstein T; Whelan CJ; Lane T; Gilbertson JA; Rowczenio D; Hawkins PN; Gillmore JD
    Eur Heart J Cardiovasc Imaging; 2017 Dec; 18(12):1344-1350. PubMed ID: 28159995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: An underestimated phenomenon.
    Cappelli F; Gallini C; Costanzo EN; Tutino F; Ciaccio A; Vaggelli L; Bartolini S; Morini S; Martone R; Angelotti P; Frusconi S; Di Mario C; Perfetto F
    Int J Cardiol; 2018 Mar; 254():346-350. PubMed ID: 29407121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.